US EditionPublished • loading... • Updated
Cancer Drug TECVAYLI Slows Disease in Tough-to-Treat Myeloma Patients
TECVAYLI monotherapy showed a 71% reduction in progression or death risk and 40% reduction in death risk in refractory multiple myeloma patients, with manageable safety profile.
- On Jan. 14, 2026, Johnson & Johnson announced MajesTEC-9 topline data showing TECVAYLI monotherapy cut risk of death by 40% versus standard of care.
- MajesTEC-9 enrolled patients with one to three prior lines who all had prior anti-CD38 monoclonal antibody and lenalidomide exposure, targeting those refractory to these agents.
- The study also showed CRS appeared in 95%, with Grade 1 in 50%, Grade 2 in 21%, and Grade 3 in 0.6%, and neurologic toxicity in 57% with ICANS in 6%, serious infections in 30%.
- The study's result positions TECVAYLI as a potential new standard of care, supported by the second positive MajesTEC-9 Phase 3 study and more than 20,800 patients treated since approval.
- Roberto Mina, M.D., commented that `The MajesTEC-9 results reinforce the potential of TECVAYLI to transform treatment earlier in the multiple myeloma journey`, while TECVAYLI remains available only through TALVEY REMS due to CRS and neurologic risks.
Insights by Ground AI
33 Articles
33 Articles
Bennington Banner+29 Reposted by 29 other sources
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population
Coverage Details
Total News Sources33
Leaning Left2Leaning Right2Center11Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
13%
C 74%
13%
Factuality
To view factuality data please Upgrade to Premium
